Titre
Systematic Assessment of Factors Influencing Preferences of Crohn's Disease Patients in Selecting an Anti-TNF agent (CHOOSE TNF TRIAL)
Type
abstract de conférence/colloque
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Série
Swiss Medical Weekly
Auteur(s)
Vavricka, S.R.
Auteure/Auteur
Bentele, N.
Auteure/Auteur
Scharl, M.
Auteure/Auteur
Rogler, G.
Auteure/Auteur
Zeitz, J.
Auteure/Auteur
Frei, P.
Auteure/Auteur
Straumann, A.
Auteure/Auteur
Binek, J.
Auteure/Auteur
Schoepfer, A.M.
Auteure/Auteur
Fried, M.
Auteure/Auteur
Groupes de travail
Swiss IBDnet
Liens vers les personnes
Liens vers les unités
Titre du livre ou conférence/colloque
Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society for Visceral Surgery, Swiss Association for the Study of the Liver
Adresse
Lausanne, Switzerland, September 29-30, 2011
ISBN
1424-7860
Statut éditorial
Publié
Date de publication
2011
Volume
141
Première page
10S
Peer-reviewed
Oui
Langue
anglais
Résumé
Background a nd A ims: I nfliximab (IFX), adalimumab (ADA)and certolizumab pegol (CZP) have similar efficacy for inductionand maintenance of clinical response and remission in Crohn'sdisease (CD). Given the comparable nature of t hese drugs,patients' p references m ay i nfluence the choice o f the product.Goal: to identify factors contributing to CD patients' decision inselecting one anti-TNF agent over the others.Methods: A p rospectdive s urvey was performed a mong a nti-TNF-naïve CD patients. Prior to completion of a questionnaire,patients were provided with a description of the three anti-TNFagents f ocusing on indications, route of administration, s ideeffects, and scientific evidence of efficacy and safety.Results: One hundred patients (47f/53m, mean age 45±16yrs)completed the questionnaire. Disease location was ileal, colonicand ileocolonic in 33%, 40% and 27% of patients, respectively.Thirty-six percent preferred ADA as medication of choice, while28% and 2 5% p referred CZP and IFX; 11% were u ndecided.Patients' decision in selecting an anti-TNF drug was influencedby t he following f actors: side effects ( 76%), p hysician'srecommendation (66%), route of administration (54%), efficacydata (52%), time required for therapy administration (27%),recommendations by other CD patients (21%) and interactionswith other medications (12%).Conclusions: T he majority of p atients p referred anti-TNFmedications t hat were a dministered by s ubcutaneous i njectionrather t han b y intravenous i nfusion. Side effect profile andphysicians' r ecommendation are t wo m ajor factors influencingthe patients' s election of a specific anti-TNF d rug. Patients'concerns about safety and lifestyle habits should be taken intoaccount when prescribing anti-TNF drugs.
PID Serval
serval:BIB_7AAECB19FCEF
Date de création
2012-03-22T16:42:47.449Z
Date de création dans IRIS
2025-05-21T00:06:14Z